WALTHAM, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2009 results on Monday, May 11, 2009. A conference call and webcast hosted by OXiGENE management will begin at 4:30 p.m. EDT (1:30 p.m. PDT).
To listen to a live or archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investor" tab, select the link to "Events and Presentations."
OXiGENE's earnings conference call can also be heard live by dialing 877-719-9801 in the United States and Canada, and 719-325-4766 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 7:30 p.m., EDT (4:30 p.m., PDT) on May 11, 2009 and ending at 12:00 midnight EDT (9:00 p.m., PDT) on Monday, May 25, 2009. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 3405204.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969